Yunnan's self-produced plasma-derived medicinal products make debut at China-South Asia Exposition

It marked the completion of Yunnan's first industrial project of plasma-derived medicinal products with an annual processing capacity of 1,200 tons and opened a new chapter for the development of its biopharmaceutical industry.

The Provincial People's Government of Yunnan signed two strategic cooperation agreements with China National Pharmaceutical Group Co Ltd (Sinopharm) in 2017 and 2022 on the relocation of Sinopharm Shanghai Plasma-derived Biotherapies into Kunming-based Yunnan Dianzhong New Area.

They will also build an industrial production base of biological products as well as an affiliated plasmapheresis center. With an investment of 1.655 billion yuan (about $232.53 million) and an area of 161.7 mu (roughly 10.78 hectares), the industrial project of biological products was formally launched in September 2019.